Share on LinkedInShare on LinkedIn

ARTICLE · 15 MAY 2026

Protected: China | Data Exclusivity Comes Into Effect

China's National Medical Products Administration has introduced new Implementation Measures for the Protection of Drug Trial Data, establishing a dual-track system of patent and data protection for pharmaceuticals. The measures grant data exclusivity periods ranging from 3 to 6 years for innovative drugs, improved new drugs, and generic drugs, with significant changes from earlier drafts including removal of time-gap reductions and extended protection for improved formulations.

ChinaFood, Drugs, Healthcare, Life Sciences

The National Medical Products Administration (NMPA) released the Implementation Measures for the Protection of Drug Trial Data on 15 May 2026 with immediate effect, i.e. simultaneously with the Implementing Regulations of the Drug Administration Law (2026 Revisions). The enforcement of the official Measures brings China’s pharmaceutical intellectual property protection into a new dual-track era of patent and data protection.

The final measures confirm that data protection (data exclusivity) is prescribed for innovative drugs, improved new drugs, and generic drugs per the Applicant’s request and with respect to the self-obtained and undisclosed trial data and other data submitted by the Applicant.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from